NVAX
Novavax, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 13,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "40e7b82e-6008-4bf8-bc31-8949ab3cae5b",
"title": "Market Today: GameStop and AMC Surge Amid Meme Stock Frenzy",
"description": "The major stock indices ended the day mixed after starting with initial gains, driven by recent positive momentum. The S&P 500 remained relatively unchanged com",
"keywords": "GuruFocus, Article, News, GuruFocus Research, GME, AMC, NVAX, TUP, GOOG, AAPL, BYDDF, BTC, WBA, ZIM, KVUE, NVDA, INTC, AMD, HD, CSCO, WMT, GME, BYON, KOSS, AMC",
"snippet": "The major stock indices ended the day mixed after starting with initial gains, driven by recent positive momentum. The S&P 500 remained relatively unchanged com...",
"url": "https://www.gurufocus.com/news/2436477/market-today-gamestop-and-amc-surge-amid-meme-stock-frenzy",
"image_url": "https://static.gurufocus.com/1732803573856661504.png",
"language": "en",
"published_at": "2024-05-13T22:32:25.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.859133,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "Other notable stocks on this list included <em>Novavax</em> (NVAX, Financial), AMC (AMC, Financial), and Tupperware Brands (TUP, Financial), all experiencing significant price movements. This list highlights stocks that are heavily shorted and thus potential targets for similar buying surges.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "00b503db-18f2-47ff-a915-d1aa366d0a1d",
"title": "After-hours movers: AMC Entertainment, StoneCo, Fulcrum Therapeutics, and more By Investing.com",
"description": "After-hours movers: AMC Entertainment, StoneCo, Fulcrum Therapeutics, and more",
"keywords": "",
"snippet": "After-Hours Stock Movers:\n\nAMC Entertainment (NYSE: ) rose 17%, extending gains after surging 78% during the regular session amid a rally in so-called meme stoc...",
"url": "https://www.investing.com/news/stock-market-news/afterhours-movers-amc-entertainment-stoneco-fulcrum-therapeutics-and-more-432SI-3438153",
"image_url": "https://i-invdn-com.investing.com/news/moved_LYNXNPEH590HU_L.jpg",
"language": "en",
"published_at": "2024-05-13T20:48:10.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 20.431229,
"sentiment_score": 0.4939,
"highlights": [
{
"highlight": "<em>Novavax</em> (NASDAQ: ) rose 2% after climbing 48% earlier today amid a mixture of excitement about its recent pact with Sanofi (NASDAQ: ) and short covering.\n\nStoneCo (STNE) fell 6% after reporting EPS and revenue that trailed estimates in the first quarter.\n\nFulcrum Therapeutics Inc.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "8cc81367-30b0-4d59-8e37-e93caa2eec2a",
"title": "Bolsas de NY fecham mistas, em sessão com expectativas por dados de inflação nos EUA",
"description": "Dados de inflação devem oferecer sinalizações sobre os próximos passos para a política monetária",
"keywords": "",
"snippet": "Publicidade\n\nAs bolsas de Nova York fecharam sem sinal único nesta segunda-feira, 13, em uma sessão de agenda esvaziada em indicadores macroeconômicos. Inves...",
"url": "https://www.infomoney.com.br/mercados/bolsas-de-ny-fecham-mistas-em-sessao-com-expectativas-por-dados-de-inflacao-nos-eua/",
"image_url": "https://www.infomoney.com.br/wp-content/uploads/2024/01/406101274.jpg?quality=70",
"language": "pt",
"published_at": "2024-05-13T20:42:00.000000Z",
"source": "infomoney.com.br",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.49967,
"sentiment_score": null,
"highlights": [
{
"highlight": "Seguindo o movimento, AMC saltou 78,35%, Faraday Future Intelligent Electric ganhou 32,32% e <em>Novavax</em> subiu 47,64%.\n\nO American Depositary Receipt (ADR) da fabricante de chips Arm subia 7,71%, após a notícia de que a empresa planeja lançar semicondutores de inteligência artificial (IA) em 2025.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "d86733fe-4154-491d-9ce7-65c7ef03f2c8",
"title": "Рынок акций США закрылся разнонаправленно, Dow Jones снизился на 0,21% От Investing.com",
"description": "Рынок акций США закрылся разнонаправленно, Dow Jones снизился на 0,21%",
"keywords": "",
"snippet": "Investing.com – Фондовый рынок США завершил торги понедельника разнонаправленно за счет укр?...",
"url": "https://ru.investing.com/news/stock-market-news/article-2419110",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPED0307W_L.jpg",
"language": "ru",
"published_at": "2024-05-13T20:30:48.000000Z",
"source": "ru.investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 35.732216,
"sentiment_score": null,
"highlights": [
{
"highlight": "См. подробностиили\n\nВ лидерах роста среди компонентов индекса NASDAQ Composite по итогам сегодняшних торгов были акции CareCloud Inc (NASDAQ: ), которые подорожали на 84,13% до отметки 2,32, VinFast Auto (NASDAQ: ), которые набрали 51,50%, закрывшись на уровне 4,56, а также акции <em>Novavax</em> <em>Inc</em> (NASDAQ: ), которые повысились на 47,64%, завершив сессию",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "Котировки акций <em>Novavax</em> <em>Inc</em> (NASDAQ: ) выросли до 52-недельного максимума, поднявшись на 47,64%, 4,23 п., и завершили торги на отметке 13,11.\n\nИндекс волатильности , который формируется на основе показателей торговли опционами на S&P 500, вырос на 8,37% до отметки 13.60.",
"sentiment": 0.6124,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "b4d8f3a8-f9b6-4728-95f4-d36a2895edc1",
"title": "U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.21% By Investing.com",
"description": "U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.21%",
"keywords": "",
"snippet": "Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the , and sectors led shares higher while losses in the , and sectors led shares...",
"url": "https://www.investing.com/news/stock-market-news/us-stocks-mixed-at-close-of-trade-dow-jones-industrial-average-down-021-3438021",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPECBL0J0_L.jpg",
"language": "en",
"published_at": "2024-05-13T20:30:24.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.820225,
"sentiment_score": 0.56955,
"highlights": [
{
"highlight": "See disclosureor\n\nThe top performers on the NASDAQ Composite were CareCloud Inc (NASDAQ: ) which rose 84.13% to 2.32, VinFast Auto (NASDAQ: ) which was up 51.50% to settle at 4.56 and <em>Novavax</em> <em>Inc</em> (NASDAQ: ) which gained 47.64% to close at 13.11.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Shares in <em>Novavax</em> <em>Inc</em> (NASDAQ: ) rose to 52-week highs; gaining 47.64% or 4.23 to 13.11.\n\nThe , which measures the implied volatility of S&P 500 options, was up 8.37% to 13.60.\n\nGold Futures for June delivery was down 1.37% or 32.60 to $2,342.40 a troy ounce.",
"sentiment": 0.6124,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "d2e24064-fe1e-47a8-aaab-3e6b18c091d3",
"title": "Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal",
"description": "Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.",
"keywords": "stock, stocks, investment, investment advice, investing, online trading, online investment, online stock trading, stock market, financial, financial planning, quote, quotes, stock quotes",
"snippet": "This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...",
"url": "https://www.zacks.com/stock/news/2273100/novavax-nvax-q1-earnings-miss-stock-soars-on-sanofi-deal?cid=CS-ZC-FT-analyst_blog|earnings_article-2273100",
"image_url": "https://staticx-tuner.zacks.com/images/articles/main/8a/2449.jpg",
"language": "en",
"published_at": "2024-05-13T16:51:00.000000Z",
"source": "zacks.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.97289,
"sentiment_score": -0.1531,
"highlights": [
{
"highlight": "<em>Novavax</em> (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal",
"sentiment": -0.1531,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "8d0fbc9d-4595-43ff-9145-99c800123046",
"title": "Novavax shares price target raised on Sanofi deal By Investing.com",
"description": "Novavax shares price target raised on Sanofi deal",
"keywords": "",
"snippet": "On Monday, Novavax , Inc. (NASDAQ: ) saw its stock price target increased by a TD Cowen analyst. The new target is set at $10.00, a significant rise from the pr...",
"url": "https://www.investing.com/news/company-news/novavax-shares-price-target-raised-on-sanofi-deal-93CH-3437593",
"image_url": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
"language": "en",
"published_at": "2024-05-13T15:45:02.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.120464,
"sentiment_score": 0.412389,
"highlights": [
{
"highlight": "On Monday, <em>Novavax</em> , <em>Inc</em>. (NASDAQ: ) saw its stock price target increased by a TD Cowen analyst. The new target is set at $10.00, a significant rise from the previous $5.00, while the firm maintains a Hold rating on the stock.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "The adjustment follows Novavax's announcement of a substantial licensing agreement with Sanofi (NASDAQ: ), which includes an upfront payment of $570 million to <em>Novavax</em> and up to $700 million more tied to development milestones for the company's COVID-19 mono and potential flu combo vaccines.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "The financial infusion from Sanofi is viewed as a positive development for <em>Novavax</em>, providing a longer cash runway for the company's platform.\n\nDespite the optimism surrounding the Sanofi deal, the analyst noted that <em>Novavax</em> has lowered its sales guidance for the fiscal year 2024 and acknowledged a first-quarter miss.",
"sentiment": 0.1944,
"highlighted_in": "main_text"
},
{
"highlight": "The licensing deal with Sanofi is a key strategic move for <em>Novavax</em>, as it aims to advance its vaccine candidates and strengthen its financial position. The upfront payment and potential milestone payments could significantly support the company's development efforts in the coming years.",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "The analyst's comments suggest that while the market for COVID-19 vaccines remains unpredictable, the collaboration with a major pharmaceutical player like Sanofi could provide <em>Novavax</em> with the resources needed to navigate the challenges ahead.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Despite a challenging fiscal environment, <em>Novavax</em> has seen a remarkable total return of 107.48% over the last month, which aligns with the positive sentiment surrounding the Sanofi deal.",
"sentiment": 0.792,
"highlighted_in": "main_text"
},
{
"highlight": "InvestingPro Tips highlight that <em>Novavax</em> is quickly burning through cash and does not pay a dividend, which might be considerations for investors prioritizing cash flow and income. The stock's volatility is also underscored by the fact that it's trading near its 52-week high, with an RSI suggesting it is in overbought territory.",
"sentiment": 0.3648,
"highlighted_in": "main_text"
},
{
"highlight": "For those looking for a comprehensive analysis of <em>Novavax</em>, InvestingPro offers additional insights, including a total of 14 InvestingPro Tips for the company, which can be accessed through their subscription service.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novavax</em> shares price target raised on Sanofi deal By Investing.com",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "10e386aa-e628-4172-86cb-b9d26076d367",
"title": "Global Preventive Vaccines Market Size To Exceed USD 101.22 Billion By 2033 | CAGR Of 1.37%",
"description": "The Global Preventive Vaccines Market Size was valued at USD 88.34 Billion in 2023 and The Worldwide Preventive Vaccines Market Size is expected to reach...",
"keywords": "SPHERICAL INSIGHTS LLP, Preventive Vaccines Market, Preventive Vaccines Size, Preventive Vaccines Share, Preventive Vaccines Trend, Growth, Analysis, Price",
"snippet": "New York, United States, May 13, 2024 (GLOBE NEWSWIRE) -- The Global Preventive Vaccines Market Size is to Grow from USD 88.34 Billion in 2023 to USD 101.22 Bil...",
"url": "https://www.globenewswire.com/news-release/2024/05/13/2880588/0/en/Global-Preventive-Vaccines-Market-Size-To-Exceed-USD-101-22-Billion-By-2033-CAGR-Of-1-37.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/b27a94e8-407e-46ae-a5c2-47bb2a1c8a2e",
"language": "en",
"published_at": "2024-05-13T14:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.463475,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "Major vendors in the global preventive vaccines market are <em>Novavax</em> <em>Inc</em>., Daiichi Sankyo Company Limited, GSK PLC, Sanofi, Johnson & Johnson, Merck & Co., Takeda Pharmaceutical Co. Ltd, AstraZeneca PLC, Emergent BioSolutions Inc., and others.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "fd775750-1ad2-4182-be59-088d7d0811b2",
"title": "Novavax Starts A New Chapter, Turning The Page On Financial Uncertainty",
"description": "Just when the Covid-vaccine maker Novavax Inc.'s (NVAX) future as a going concern seemed uncertain, a remarkable turnaround has unfolded, thanks to the license deal with Sanofi (SNY).",
"keywords": "EU, FDA, COVID-19, triple-gainers",
"snippet": "Just when the Covid-vaccine maker Novavax Inc.'s (NVAX) future as a going concern seemed uncertain, a remarkable turnaround has unfolded, thanks to the license ...",
"url": "https://www.rttnews.com/3447260/novavax-starts-a-new-chapter-turning-the-page-on-financial-uncertainty.aspx?type=ts",
"image_url": "https://cdn.rttnews.com/articleimages/ustopstories/2024/may/happysadinvestors-may13-lt.jpg",
"language": "en",
"published_at": "2024-05-13T11:06:54.000000Z",
"source": "rttnews.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.807037,
"sentiment_score": 0.289373,
"highlights": [
{
"highlight": "Just when the Covid-vaccine maker <em>Novavax</em> <em>Inc</em>.'s (NVAX) future as a going concern seemed uncertain, a remarkable turnaround has unfolded, thanks to the license deal with Sanofi (SNY).",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "The deal signed with Sanofi on May 10, 2024, relates to Covid-19 vaccine and Covid/Influenza combination vaccine candidate, representing a potential multi-billion-dollar revenue opportunity for <em>Novavax</em>.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Novavax's Covid-19 vaccine is authorized in select geographies under trade names <em>Novavax</em> Covid-19 Vaccine, Adjuvanted; Covovax; and Nuvaxovid, authorized in the U.S under trade name, <em>Novavax</em> Covid-19 Vaccine, Adjuvanted, and authorized in the EU under the trade name Nuvaxovid XBB.1.5.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novavax</em> maintains ownership of its Covid-19 Influenza Combination vaccine candidate.\n\n-- Sanofi also acquires a non-exclusive license to deploy Novavax's adjuvanted Covid-19 vaccine with non-flu vaccines.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "How much is the deal worth for <em>Novavax</em>?\n\n<em>Novavax</em> is set to receive an initial payment of $500 million, with the potential for up to $700 million in further payments tied to developmental, regulatory, and launch milestones, equating to approximately $1.2 billion.",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novavax</em> will be entitled to tiered double-digit percentage royalties on the sales of both Covid-19 vaccines and Covid-19-Influenza Combination vaccines by Sanofi.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novavax</em> stands to gain extra milestone opportunities worth up to $200 million tied to launches and sales, along with mid-single digit royalties for every additional vaccine product developed by Sanofi using Novavax's Matrix-M adjuvant under a non-exclusive license.",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, as part of the agreement, Sanofi will make an equity investment of approximately $70 million for a minority equity investment (less than 5%) in <em>Novavax</em>.\n\nWhat Led <em>Novavax</em> Report Going Concern Matters in 2023?\n\nIn February 2023, the company faced significant uncertainties about its future viability.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, <em>Novavax</em> was dealing with a pending arbitration with Gavi, the Vaccine Alliance, related to its 2021 Advance Purchase Agreement for its Covid-19 vaccine prototype.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "As part of the settlement, <em>Novavax</em> made an initial payment of $75 million to Gavi and committed to making deferred payments of $80 million annually until December 31, 2028, totaling up to $400 million.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novavax</em> Starts A New Chapter, Turning The Page On Financial Uncertainty",
"sentiment": -0.34,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "54122b3b-d4d9-41bb-b03b-ed8cb1afe102",
"title": "Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket - JanOne (NASDAQ:JAN)",
"description": "",
"keywords": "",
"snippet": "Loading... Loading...\n\nShares of JanOne Inc. JAN rose sharply in today's pre-market trading after the company announced plans to acquire ALT 5 Sigma Inc.\n\nThe d...",
"url": "https://www.benzinga.com/news/24/05/38783309/why-janone-shares-are-trading-higher-by-19-here-are-20-stocks-moving-premarket",
"image_url": "https://cdn.benzinga.com/files/images/story/2024/05/13/wall-street-subway-shutter.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2024-05-13T09:46:10.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVAX",
"name": "Novavax, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 20.15322,
"sentiment_score": 0.81375,
"highlights": [
{
"highlight": "<em>Novavax</em> <em>Inc</em> NVAX gained 8.2% to $9.61 in pre-market trading. <em>Novavax</em> shares jumpd 99% on Friday after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and develop COVID-influenza combination vaccines.\n\ngained 8.2% to $9.61 in pre-market trading.",
"sentiment": 0.8625,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novavax</em> shares jumpd 99% on Friday after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and develop COVID-influenza combination vaccines. Groupon, Inc. GRPN shares rose 7.1% to $13.88 in pre-market trading.",
"sentiment": 0.765,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NVAX",
"total_documents": 13,
"sentiment_avg": 0.33269281820817426
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- Healthcare
- us